NGeneBio Co., Ltd. (KOSDAQ:354200)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,682.00
+21.00 (1.26%)
At close: Apr 3, 2026
Market Cap43.38B +29.0%
Revenue (ttm)21.24B +61.7%
Net Income-5.54B
EPS-247.00
Shares Out26.12M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,724
Average Volume318,861
Open1,684.00
Previous Close1,661.00
Day's Range1,641.00 - 1,705.00
52-Week Range1,325.00 - 2,765.00
Beta1.31
RSI36.38
Earnings DateMar 27, 2026

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 354200
Full Company Profile

Financial Performance

In 2024, NGeneBio's revenue was 5.69 billion, an increase of 30.80% compared to the previous year's 4.35 billion. Losses were -12.63 billion, -1.11% less than in 2023.

Financial Statements